Pancreatic Cancer Research

ResearcherSichuan UniversityNo recent work listed

DuJiang Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0597-1143; OpenAlex author ID A5029559555. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
10
Papers, trials and grants by year

2019: 4 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper

Papers 8

  1. Single-minded homolog 2 as a potential prognostic signature and assessment of its correlation with immune cell infiltration in pancreatic cancer. Co-author DOI 10.5114/pjp.2023.134317↗
  2. LncRNA GAS8-AS1 is a Novel Prognostic and Diagnostic Biomarker for Pancreatic Cancer. Co-author DOI 10.1615/critreveukaryotgeneexpr.2022039770↗
  3. Long Non-Coding RNA MIR4435-2HG Promotes Glycolysis and Tumor Immunity in Pancreatic Cancer Through Absorption of microRNA-582-5p to Target GPX8 Co-author DOI 10.21203/rs.3.rs-1112369/v1↗
  4. miR-25 expression is upregulated in pancreatic ductal adenocarcinoma and promotes cell proliferation by targeting ABI2. Co-author DOI 10.3892/etm.2020.8595↗
  5. The oncological safety in minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Co-author DOI 10.1038/s41598-018-37617-0↗
  6. MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy. Co-author DOI 10.1042/bsr20181374↗
  7. Downregulation of LINC01638 lncRNA inhibits migration and invasion of pancreatic ductal adenocarcinoma cells by reducing TGF‑β signaling. Co-author DOI 10.3892/mmr.2019.10699↗
  8. Linc-pint inhibits early stage pancreatic ductal adenocarcinoma growth through TGF-β pathway activation. First author DOI 10.3892/ol.2019.10111↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Huimin Lü · 8 shared papers, 2019–2023 · strength 1.06
  2. Li Mao · 6 shared papers, 2019–2023 · strength 0.78
  3. Weiming Hu · 5 shared papers, 2019–2020 · strength 0.55
  4. Zuowei Wu · 1 shared paper, 2023 · strength 0.19
  5. Qian Hu · 1 shared paper, 2023 · strength 0.19
  6. Ling Zhang · 1 shared paper, 2022 · strength 0.17
  7. Weiming Hu · 1 shared paper, 2021 · strength 0.14
  8. Zhenlu Li · 1 shared paper, 2021 · strength 0.14
  9. Ling Zhang · 1 shared paper, 2019 · strength 0.11
  10. Junjie Xiong · 1 shared paper, 2019 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.